Basic & Clinical Pharmacology & Toxicology最新文献

{"title":"An extended substrate spectrum of the proton organic cation antiporter and relation to other cation transporters.","authors":"Cauzar Ali Khan, Nicolai Kirsch, Jürgen Brockmöller, Kyra-Elisa Maria Redeker","doi":"10.1111/bcpt.14090","DOIUrl":"https://doi.org/10.1111/bcpt.14090","url":null,"abstract":"<p><p>Most central nervous system (CNS) active drugs are organic cations, which need carrier proteins for efficient transfer through the blood-brain barrier (BBB). A genetically still unidentified proton organic cation (H⁺/OC) antiporter is found in several tissues, including endothelial cells of the BBB. We characterized the substrate spectrum of the H⁺/OC antiporter and the overlap in substrate spectrum with OCTN1, OCTN2 or OCT3 by screening 87 potential substrates for transport activity. Based on high antiport rates, 45 of the tested substances were substrates of the H⁺/OC antiporter. They included antidepressants (like tranylcypromine or nortriptyline), antipsychotics (like levomepromazine) and local anaesthetics. Concentration-dependent transport was confirmed for 38 of the substrates. Transport uptake depending on a pH gradient across the cell membrane confirmed that 43 drugs were indeed substrates of the H⁺/OC antiporter. However, the patterns of pH dependence differed between the substrates, possibly indicating different modes of transport or the existence of multiple antiporter proteins. The substrate overlap between the H⁺/OC antiporter and OCTN1, OCTN2 or OCT3 was minimal, indicating that the latter three are not the proteins underlying the H⁺/OC antiporter activity. Overall, about 50% of positively charged drugs may be substrates of the antiporter, which may be the most important membrane transport protein for many drugs.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The active ingredient of Evodia rutaecarpa reduces inflammation in knee osteoarthritis rats through blocking calcium influx and NF-κB pathway.","authors":"Yan Gao, Sixiang Wang, Yuehong Gao, Li Yang","doi":"10.1111/bcpt.14096","DOIUrl":"https://doi.org/10.1111/bcpt.14096","url":null,"abstract":"<p><p>Chronic inflammation significantly contributes to the progression of osteoarthritis (OA), and an anti-inflammatory small molecule derived from medicinal herbs could be a potential drug candidate for OA. Herein, we investigated the function and mechanism of Evodiamine (EAE), the active ingredient from Evodia rutaecarpa, in chondrocytes and macrophages in vitro and in vivo. The cytotoxicity of EAE was determined using an MTT assay. And the anti-inflammatory and anti-extracellular matrix (ECM) degradation effects of EAE were investigated using qRT-PCR, western blot (WB), immunofluorescence (IF). Inductively Coupled Plasma Atomic Emission Spectrometry (ICP-AES), Fluo-4 AM, IF and AutoDock were used to elucidate the molecular mechanisms and signalling pathways of the reducing-inflammatory properties of EAE on chondrocytes in vitro. Moreover, the effect of EAE on macrophage polarization was detected by IF and flow cytometry (FC). Ultimately, we explored the in vivo therapeutic efficacy of EAE in an anterior cruciate ligament transection (ACLT)-induced OA model. The finding demonstrated that EAE blocked the phosphorylation of IKBα and Ca²⁺ influx, thereby curbing inflammation and ECM degradation. Additionally, EAE can prevent the polarization towards the M1 phenotype. Thus, our findings suggest that EAE has great potential as a therapeutic drug for the treatment of OA.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of weekly versus daily cholecalciferol for repleting serum vitamin D (25(OH)D) deficiency: A systematic review and meta-analysis of randomized controlled trials.","authors":"Émilie Bortolussi-Courval, Connor Prosty, Jimin J Lee, Lisa M McCarthy, Emily G McDonald, Todd C Lee","doi":"10.1111/bcpt.14092","DOIUrl":"https://doi.org/10.1111/bcpt.14092","url":null,"abstract":"<p><strong>Background/rationale: </strong>Weekly cholecalciferol can replace daily supplementation to reduce pill burden in patients with complex medication regimens and hypovitaminosis D, but evidence supporting this switch is unclear.</p><p><strong>Objective: </strong>We aimed to determine whether weekly cholecalciferol was superior to daily cholecalciferol to replete patients with hypovitaminosis D.</p><p><strong>Methods: </strong>We conducted a systematic review of randomized controlled trials involving participants with baseline hypovitaminosis D (<30 ng/ml) comparing weekly versus daily cholecalciferol dosing and where serum cholecalciferol was measured within 120 days of starting treatment. We searched MEDLINE, CINAHL and EMBASE from inception to 7 May 2024. A random-effects meta-analysis evaluated the odds ratio for repletion of serum vitamin D levels.</p><p><strong>Findings: </strong>Eight trials involving 542 patients were included in the analysis. Weekly and daily cholecalciferol were not significantly different in correcting hypovitaminosis D (OR = 1.5, 95% CI = 0.3-6.9, p = 0.6, favouring weekly dosing, I² = 85.3%). A sensitivity analysis excluding otherwise healthy patients had similar findings (OR = 0.8, 95% CI = 0.3-2.1, p = 0.6). Most studies were at risk of bias; the different doses being compared increased the heterogeneity.</p><p><strong>Conclusions: </strong>Limited direct evidence supports a switch from daily to weekly cholecalciferol dosing; however, weekly supplementation was not demonstrably worse at repleting levels and decreased a patient's daily pill burden.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to ‘register-based study on prescription renewal without the prescriber meeting the patient’","authors":"","doi":"10.1111/bcpt.14093","DOIUrl":"https://doi.org/10.1111/bcpt.14093","url":null,"abstract":"<p>\u0000 <span>Rönngård-Jalkanen, A</span>, <span>Aarnio, E</span>, <span>Saastamoinen, L</span>, <span>Timonen, J</span>. <span>Register based study on prescription renewal without the prescriber meeting the patient</span>. <i>Basic Clin Pharmacol Toxicol</i> <span>2024</span>; <span>135</span>(<span>3</span>): <span>321</span>-<span>333</span>. doi:10.1111/bcpt.14049</p><p>In the above article, the Data Availability Statement is shown as ‘The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethics restrictions’.</p><p>The correct statement should be</p><p>We apologize for this error.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 5","pages":"665"},"PeriodicalIF":2.7,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14093","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142443535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase I clinical trial evaluating the safety, tolerance, pharmacokinetics and pharmacodynamics of HSK21542 injection in healthy volunteers.","authors":"Rong Shao, Hai-Ying Wang, Zou-Rong Ruan, Bo Jiang, Dan-Dan Yang, Yin Hu, Yi-Chao Xu, Jin-Ting Yang, Wei Gao, Wan-Yun Zhao, Min Yan, Honggang Lou","doi":"10.1111/bcpt.14094","DOIUrl":"https://doi.org/10.1111/bcpt.14094","url":null,"abstract":"<p><p>HSK21542 injection is a new peripheral kappa opioid receptor (KOR) agonist. To evaluate its safety, tolerability, pharmacokinetics and pharmacodynamics, this study was conducted in healthy volunteers, consisting of two parts: a single ascending dose (0.2-3.375 μg/kg, 15-min infusion) and different infusion durations (0.2 and 1 μg/kg, 2- or 15-min infusion). The area under the plasma concentration-time curve (AUC) and peak concentration (C_max) of HSK21542 were dose-linear among 0.2-3.375 μg/kg. After intravenous injection, HSK21542 was rapidly eliminated with a half-life (t_1/2) of 1.5 h, and the majority (48.02%) of the dose was excreted unchanged in urine. Pharmacodynamic results showed that HSK21542 increased prolactin release and reached a peak at 1-2 h after administration but had no significant effect on vasopressin levels. There was a brief increase in urine volume within the initial 2 h after administration. HSK21542 was well tolerated; most of the adverse effects (AEs) in the trial group were grade 1, and only 2 cases (4.0%) were grade 2. The main AE was paresthesia, which appeared in 42% (21/50) in the trial group. No serious adverse event (SAE) was observed. No subject withdrew early due to AEs. These results suggest that HSK21542 may be a potential treatment for pain and pruritic conditions.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-4 promotes chondrogenesis of bone marrow mesenchymal stem cells and blockade of IL-4Rα retards the endochondral ossification during rat embryonic bone development.","authors":"Yimeng Hao, Qinghe Meng, Leilei Chang, Minglong Qiu, Jianxin Han, Zhiqin Wang, Changwei Li, Jing Ma, Xuemei Zhang","doi":"10.1111/bcpt.14088","DOIUrl":"https://doi.org/10.1111/bcpt.14088","url":null,"abstract":"<p><p>Interleukin-4 (IL-4)/IL-4 receptor alpha (IL-4Rα) signalling pathways play important roles in the complex process of bone formation and bone remodelling. However, whether IL-4/IL-4Rα participates in skeletogenesis during embryonic development is not completely understood. We used the anti-IL-4Rα monoclonal antibody (anti-IL-4Rα mAb) as a powerful investigational tool to evaluate the potential roles of IL-4/IL-4Rα in the chondrogenic differentiation of rat bone marrow mesenchymal stem cells (BMSCs) in vitro. Simultaneously, we explored the effect of IL-4/IL-4Rα on bone ossification during rat embryo-fetal development. In this study, we found that, compared to the control group, IL-4 can significantly promote the chondrogenic differentiation of BMSCs. Furthermore, following exposure to anti-IL-4Rα mAb in pregnant rats, unexpected phenomena were observed in fetal bone development, including non-ossification of the fetal sternum, an incomplete ossification centre in long bones and a reduced number of ossification points in digit (toe) bones. To further investigate the underlying mechanism of the phenotype, we studied the rat sternum as the target organ, starting from different time points of sternum development in the embryonic stage. The results indicated that the retardation mainly occurred in the middle and late stages of embryonic development. This retardation was characterized by the inhibition of the differentiation process of mesenchymal stem cells into chondrocytes, resulting in reduced angiogenesis near the ossification centre, failure of osteoblasts to invade the centre of the cartilage body with the blood vessels and delayed formation of the primary ossification centre (POC). Overall, our study demonstrated the significant function of IL-4/IL-4Rα in chondrogenic differentiation of BMSCs and bone ossification during embryo-fetal development.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving CYP2C19 phenotyping using stereoselective omeprazole and 5-hydroxy-omeprazole metabolic ratios.","authors":"Kenza Abouir, Emmanuel Varesio, Julien Déglon, Caroline Samer, Youssef Daali","doi":"10.1111/bcpt.14095","DOIUrl":"https://doi.org/10.1111/bcpt.14095","url":null,"abstract":"<p><p>Omeprazole (OME) is a CYP2C19 phenotyping probe, marketed as a racemic (S)/(R) mixture or as an S-enantiomer. Both CYP2C19 and CYP3A4 enzymes mediate (R)-OME hydroxylation to (R)-5-hydroxyomeprazole, while (S)-OME is exclusively hydroxylated via CYP2C19. This study investigates OME and its 5-hydroxymetabolite enantiomers' pharmacokinetics using data from two studies involving healthy volunteers. In Study A, volunteers received OME alone in Session 1, OME combined with voriconazole and fluvoxamine in Session 2 and finally OME with rifampicin in Session 3. In Study B, volunteers received OME alone in Session 1, OME combined with voriconazole in Session 2 and finally OME with fluvoxamine in Session 3. Despite low metabolic ratio values of (S)-OME, detectable modulation of CYP2C19 activity suggests both (R)- and (S)-OME isomers could effectively assess CYP2C19 activity. Further research is needed for precise cut-offs in different phenotype groups.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142387559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Poster","authors":"","doi":"10.1111/bcpt.14066","DOIUrl":"10.1111/bcpt.14066","url":null,"abstract":"&lt;p&gt;&lt;b&gt;#8&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Immune checkpoint inhibitors and metabolic-endocrine disorders in the US FDA adverse event reporting system: Preliminary results&lt;/b&gt;&lt;/p&gt;&lt;p&gt;G. Prada Ramallal&lt;sup&gt;1&lt;/sup&gt;, L. Romero &lt;sup&gt;2&lt;/sup&gt; and R. Nogueiras Álvarez&lt;sup&gt;3&lt;/sup&gt;&lt;/p&gt;&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;i&gt;Clinical University Hospital of Santiago, A Coruña, Spain;&lt;/i&gt; &lt;sup&gt;2&lt;/sup&gt;&lt;i&gt;Technical Secretariat of the Medical Research Ethics Committee of Galicia (CEImG), Spain;&lt;/i&gt; &lt;sup&gt;3&lt;/sup&gt;&lt;i&gt;University Hospital Galdakao-Usansolo, Vizcaya, Spain&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; Immune checkpoint inhibitors (ICIs) have gained importance in cancer treatment because of their potential to contribute to long-term remission and cure. Although the benefits outweigh the risks, potential serious side effects must be considered, such as immune-related metabolic-endocrine adverse events (AEs). These AEs may correlate with increased progression-free survival and overall survival in ICIs; however, their role as predictive biomarkers is underexplored. Our study aimed to characterize the spectrum, frequency and clinical characteristics of immune-related metabolic-endocrine AEs, as well as other non-specific AEs, associated with ICIs and reported to the FDA Adverse Event Reporting System (FAERS).&lt;/p&gt;&lt;p&gt;&lt;b&gt;Material and/or methods:&lt;/b&gt; Data were collected from the FAERS database covering the period from the first quarter of 2012 to the fourth quarter of 2023. The definition relied on System Organ Class and Preferred Terms by the Medical Dictionary for Regulatory Activities (MedDRA). A preliminary descriptive analysis was then performed using R software (version 4.2.3). A Sankey diagram was built with the networkD3 package.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Results:&lt;/b&gt; The total number of AEs in FAERS related to the selected drugs was 209 065. AEs were more common in men (53.9%) than women (34.8%). People over 65 years of age account for 40.1% of total AEs. Endocrine disorders represented 8.0% with 16 665 results. Metabolic disorders represented 9.6% with 19 983 results. The most common endocrine AEs were hypothyroidism (27.4%), adrenal insufficiency (18.6%) and hypophysitis (12.7%). The most common metabolic AEs were decreased appetite (27.9%), dehydration (12.6%) and hyponatremia (10.8%). These findings align with previous studies.&lt;/p&gt;&lt;p&gt;&lt;b&gt;Conclusions:&lt;/b&gt; This study explores the incidence of metabolic-endocrine AEs associated with ICIs treatment. The results show particularly high rates among older people and men. These findings provide a reliable basis for further comprehensive AEs' investigations. To establish reliable biomarkers for predicting the effectiveness of anti-tumour treatment, additional research and advanced statistical analyses are necessary.&lt;/p&gt;&lt;p&gt;&lt;b&gt;#10&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;Safety of defibrotide in the prevention and treatment of acute respiratory distress syndrome in patients with COVID-19&lt;/b&gt;&lt;/p&gt;&lt;p&gt;P. Rodríguez-Fortúnez&lt;sup&gt;1&lt;/sup&gt;, A. J. Martínez-Mellado&lt;sup&gt;2&lt;/sup&gt;, R. Jara-Rubio&lt;sup&gt;2&lt;/sup&gt;, P. Castro-Rebollo&lt;sup","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 S1","pages":"25-72"},"PeriodicalIF":2.7,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14066","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142387565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Round tables","authors":"","doi":"10.1111/bcpt.14062","DOIUrl":"10.1111/bcpt.14062","url":null,"abstract":"&lt;p&gt;Antoni Vallano Ferraz&lt;/p&gt;&lt;p&gt;&lt;i&gt;Medicines Department, Catalan Healthcare Service, Barcelona, Spain;&lt;/i&gt; &lt;i&gt;Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain;&lt;/i&gt; &lt;i&gt;Healthcare Management of Hospitals, Catalan Institute of Health, Barcelona, Spain&lt;/i&gt;&lt;/p&gt;&lt;p&gt;The evolving landscape of drug authorization processes in the European Union (EU), with several actions to accelerate regulatory process and the access to innovative medicines, has been a response to the pressing need for increased access to innovative medicines, particularly for rare diseases, and unmet medical conditions. While this flexibility has undoubtedly expedited the availability of potentially life-saving treatments, based more in expectative that in robust evidence, it has concurrently ushered in a host of challenges that warrant careful consideration.&lt;/p&gt;&lt;p&gt;One of the foremost concerns pertains to the level of uncertainty tolerated during the approval of new medications. Notably, the approval of numerous oncological drugs based on surrogate endpoints, without concrete evidence of meaningful improvements in overall survival or quality of life, underscores the delicate balance between expediency and robust evidence. Furthermore, the emergence of additional toxicities associated with many of these approved drugs raises pertinent questions about the net clinical benefit conferred by these treatments.&lt;/p&gt;&lt;p&gt;The adoption of methodologies in clinical trials that permit early termination in response to favourable interim analyses introduces a layer of complexity, as premature cessation can inadvertently overestimate treatment effects, especially in the absence of rigorous blinding or controlled designs. This underscores the imperative for stringent scrutiny of trial data to ensure the reliability and generalizability of findings.&lt;/p&gt;&lt;p&gt;In parallel, drugs catering to niche patient populations, such as orphan medicinal products (OMPs) and advanced therapy medicinal products (ATMPs), often grapple with methodological limitations in clinical trials, resulting in approvals that are underpinned by scant evidence of efficacy and safety. This poses a considerable challenge for healthcare providers tasked with the management of the intricacies of treatment decisions in such contexts.&lt;/p&gt;&lt;p&gt;The pricing and reimbursement (P&amp;R) landscape, too, is fraught with complexities, as stakeholders endeavour to strike a delicate balance between ensuring equitable access to innovative therapies and safeguarding the fiscal sustainability of healthcare systems. Manufacturers' propensity to overestimate the cost-effectiveness of their products often leads to disparate pricing and reimbursement decisions across jurisdictions, exacerbating disparities in patient access.&lt;/p&gt;&lt;p&gt;Addressing these multifaceted challenges necessitates an approach based on multiple factors. Enhancing the scientific rigour of clinical trials through robust methodologies and tran","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 S1","pages":"9-14"},"PeriodicalIF":2.7,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14062","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142387561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scientific program","authors":"","doi":"10.1111/bcpt.14065","DOIUrl":"10.1111/bcpt.14065","url":null,"abstract":"&lt;p&gt;&lt;b&gt;WEDNESDAY 16 OCTOBER 2024&lt;/b&gt;&lt;/p&gt;&lt;p&gt;10:00–14:00&lt;b&gt;    ANNUAL MEETING OF RESEARCH ETHICS COMMITTEES&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Spanish Agency of Medicines and Medical Devices and Spanish Society of Clinical Pharmacology&lt;/p&gt;&lt;p&gt;15:30–18:30&lt;b&gt;    PRE-CONGRESS WORKSHOPS AND SEMINARS&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;“Next-generation of “deep” medicine: A look from machine learning to generative AI”&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Guillermo Prada Ramallal. &lt;i&gt;Clinical Pharmacologist, Hospital Clínico Universitario, Santiago de Compostela&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;Laura Romero Sánchez. &lt;i&gt;Technical Secretary of Research Ethics Committee of Galicia&lt;/i&gt;, &lt;i&gt;Gerencia del Servicio Gallego de Salud&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;&lt;b&gt;“Drafting and requesting competitive projects”&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Joaquín Sáez Peñataro. &lt;i&gt;Clinical Pharmacologist, Hospital Clínic, Barcelona&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;Paula López Vázquez. &lt;i&gt;Clinical Pharmacologist, Dirección Xeral de Asistencia Sanitaria-Servizo Galego de Saúde&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;&lt;b&gt;“Professional opportunities for the specialty of clinical pharmacology”&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Joaquín Sáez Peñataro. &lt;i&gt;Clinical Pharmacologist, Hospital Clínic, Barcelona&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;&lt;b&gt;“Evaluation of the therapeutic value of medicines: controversies and future perspectives”&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Arantxa Sancho López. &lt;i&gt;Clinical Pharmacologist, Head of Medical-Scientific Department of Farmaindustria&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;Emilio Vargas Castrillón. &lt;i&gt;Professor of Pharmacology, Head of Clinical Pharmacology Department, Hospital Clínico San Carlos, Universidad Complutense, Madrid&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;Pedro Zapater Hernández&lt;i&gt;. Head of Section of Clinical Pharmacology Department, Hospital General Universitario Dr. Balmis, Universidad Miguel Hernández, Alicante&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;Alejandro García Solís. &lt;i&gt;Therapeutic Positioning Reporting Area and Health Technology Assessment, Spanish Agency of Medicines and Medical Devices&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;&lt;b&gt;“Medicines in special situations”&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Concepción Payares Herrera. &lt;i&gt;Clinical Pharmacologist, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;Imma Danés Carreras. &lt;i&gt;Head of section of Clinical Pharmacology Department, Hospital Universitario Vall d'Hebron, Barcelona&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;19:00      &lt;b&gt;INAUGURATION OF THE CONGRESS&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Antònia Agustí Escasany. &lt;i&gt;President of the Spanish Society of Clinical Pharmacology&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;Emilio Vargas Castrillón. &lt;i&gt;President of the Organizing Committee of the XXXII Congress of the Spanish Society of Clinical Pharmacology&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;Guillermo Prada Ramallal&lt;i&gt;. President of the Scientific Committee of the XXXII Congress of the Spanish Society of Clinical Pharmacology&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;Carmen Durán. &lt;i&gt;General Director of Public Health, Consejería de Sanidad Gobierno Gallego&lt;/i&gt;.&lt;/p&gt;&lt;p&gt;19:30&lt;b&gt;      INAUGURAL CONFERENCE&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;“Novelties in therapeutics: Advanced therapies and other innovations”&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Cristina Avendaño Solá. Head of Clinical Pharmacology Department, Hospital Puerta de Hierro, Majadahonda, Universidad Autónoma, Madrid.&lt;/p&gt;&lt;p&gt;20:30&lt;b&gt;      WELCOME COCKTAIL&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;THURSDAY 17 OCTOBER","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"135 S1","pages":"5-8"},"PeriodicalIF":2.7,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.14065","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142387564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}